BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

SGMT

Sagimet Biosciences Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$0
$2M$1M$0
Q3 ’23Q4 ’23
Company filings · 10-K filed 12 Mar 2025 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com

Cash and cash equivalents, quarter-end

$166M+291.9% year on year
$200M$100M$0
Q3 ’23Q2 ’24Q1 ’25Q3 ’25Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

—
Not reported in this company’s filings
Company filingsvpside.com
Chart 05 is empty
Chart 06 is empty